Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2010-09-02
2011-10-18
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024310, C536S024330, C536S024500
Reexamination Certificate
active
08039446
ABSTRACT:
The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
REFERENCES:
patent: 4914210 (1990-04-01), Levenson et al.
patent: 4962029 (1990-10-01), Levenson et al.
patent: 6066500 (2000-05-01), Bennett et al.
patent: 7087229 (2006-08-01), Zhao et al.
patent: 2003/0064384 (2003-04-01), Hung et al.
patent: 2004/0235773 (2004-11-01), Zhao et al.
patent: 2009/0005335 (2009-01-01), Worm
patent: 1222309 (2005-12-01), None
patent: 01/00872 (2001-01-01), None
patent: 2004046160 (2004-06-01), None
patent: 2007031081 (2007-03-01), None
patent: 2007031091 (2007-03-01), None
patent: 2007146511 (2007-12-01), None
patent: 2008034123 (2008-03-01), None
patent: 2008053314 (2008-05-01), None
Zhang, Y. et al., “In vitro and in vivo characterization of two novel beta-catenin RNA antagonists, EZN-3889 and EZN-3892.” Enzon Pharmaceuticals, Inc. AACR Poster, Washington, D.C. 2010.
Xu et al., “Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs.” Biochemical and Biophysical Research Communications, May 2003, 306, pp. 712-717.
Veeramachanemi N.K.et al.: “Down regulation of beta catenin inhibits the growth of esophageal carcinoma cells.” The Journal of Thoracic and Cardiovascular Surgery 127:92-98, Jan. 2004.
Roh H. et al., “Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells.” Cancer Research, 61:6563-6568, Sep. 1, 2001.
Canter R.J. et al.: “Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer.” Annals of Surgical Oncology, 12:733-742, Sep. 1, 2005.
Green D.W. et al: “Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.” Journal of Surgical Research, 101:16-20, 2001.
Emanuele S. et al., “Sodium Butyrate induces apoptosis in human epatoma cells by a mitochondrial/caspase pathway, associated with degradation of beta-catenin, PRb and Bcl-XL.” European Journal of Cancer, 40:1441-1452, 2004.
Li M. et al., “Antitumor activity and chemosensitization effects of novel antisense oligonucleotides targeting beta-catenin.” Proceedings of the American Association for Cancer Research Annual Meetng, 46:137, 2005.
Heasman et al., “Overexpression of Cadherins and underexpression of beta-catenin inhibit dorsal mesoderm induction in early Xenopus embryos.” Cell 79:791-803, Dec. 1994.
Kim K. et al.: “Tissue-specific expression of beta-catenin in normal mesenchyme and uveal melanomas and its effect on invasiveness.” Experimental Cell Research 245:79-90, Jan. 1998.
International Preliminary Report on Patentability and Written Opinion issued in PCT/EP2008/055365 and dated Nov. 3, 2009.
International Search Report issued in PCT/EP2008/055365 and dated May 7, 2009.
Christensen et al., “Intercalating nucleic acids containing insertions of 1-O-(1-pyrenylmethyl)glycerol: stabilisation of dsDNA and discrimination of DNA over RNA.” Nucleic Acids Research, 30:4918-4925, 2002.
de La Coste, et al., “Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.” Proc. Natl. Acad. Sci. USA, 65:8847-8851, 1998.
Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes.” Nucleic Acids Research, 25:4429-4443, 1997.
Manoharan et al., “Novel Functionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove.” Tetrahedron Letters, 32:7171-7174, 1991.
Morin et al., “Activation of Beta-Catenin-Tcf signaling in Colon Cancer by Mutation in Beta-Catenin or APC.” Science, 275:1787-1790, 1997.
Powell et al. “APC mutations occur early during colorectal tumorigenesis.” Nature 359:235-237, 1992.
Rubinfeld, et al., “Stabilization on beta-catenin by genetic defects in melanoma cell lines.” Science 275:1790-1792, 1997.
Sparks et al., “Mutational ANalysis of the APC/Beta-Catenin-Tcf Pathway in Colorectal Cancer.” Cancer Research 58:1130-1134, 1998.
Uhlmann, “Recent advances in the medicinal chemistry of antisense oligonucleotides.” Current Opinion in Drugs Discovery & Development 3:203-213, 2000.
Zhao et al., “Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.” Journal of Controlled Release 119:143-152, 2007.
Zhao et al., “A New Platform for Oligonucleotide Delivery Utilizing the PEG Prodrug Approach.” Bioconjugate Chem., 16:758-766, 2005.
Bowman Amy
Enzon Pharmaceuticals, Inc.
Lucas & Mercanti LLP
Santaris Pharma A/S
LandOfFree
Compounds for the modulation of beta-catenin expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the modulation of beta-catenin expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the modulation of beta-catenin expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261176